<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29211212</article-id><article-id pub-id-type="pmc">5701096</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0505</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative Study of Electrical Stimulation of the Heart with VDD and
DDD Pacemakers as to the Evolution to Atrial Fibrillation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Campos</surname><given-names>Nelson Leonardo Kerdahi Leite</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>de Andrade</surname><given-names>Rubens Ramos</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fellicio</surname><given-names>Marcello Laneza</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Ant&#x000f4;nio Sergio</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Garzesi</surname><given-names>Andr&#x000e9; Monti</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Leonardo Rufino</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takeda</surname><given-names>Tassya Bueno</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">
<label>1</label> Faculdade de Medicina de Botucatu (Unesp), Botucatu, SP,
Brazil.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Nelson Leonardo Kerdahi Leite de Campos,
Av. Professor Mario Rubens Guimar&#x000e3;es Montenegro, S/N - Distrito de
Rubi&#x000e3;o Junior, Botucatu, SP, Brazil - Zip code: 18618-687. E-mail:
<email>ncampos002@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>32</volume><issue>5</issue><fpage>347</fpage><lpage>353</lpage><history><date date-type="received"><day>13</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The pacemaker implantation VDD is considered simpler, faster, less expensive
and causes fewer complications compared to DDD. However, the VDD pacemaker
has not been widely used in many centers, perhaps for fear of dysfunction of
the sinus node and the reduction of atrial sensitivity by the pacemaker
during follow-up after implantation.</p></sec><sec><title>Objective</title><p>To compare patients with DDD and VDD pacemakers regarding the evolution of
chronic atrial fibrillation (AF) and length of stay outside this
postoperative arrhythmia.</p></sec><sec><title>Methods</title><p>It was included 158 patients with dual chamber pacemakers, 48 DDD and 110
VDD. Follow-up period: between January 1, 1999 and December 31, 2015. The
mean follow-up of patients with DDD was 5.35 years and the VDD, 4.74 years.
The percentage of each group (DDD and VDD) which evolved to AF during
follow-up was assessed. Also, it was made an actuarial study with the
respective curves indicating the time free from AF for each group. Patients
were classified according to the diagnosis that led to pacemaker
implantation and the degree of heart failure.</p></sec><sec><title>Results</title><p>The percentage of patients who developed AF was higher in DDD group (10.42%)
than in VDD group (6.36%), but without statistical significance. Patients
with DDD and VDD remained free of AF for similar period.</p></sec><sec><title>Conclusion</title><p>Considering the results, the VDD pacemaker continues to be a good option to
the DDD for routine use in cases properly indicated.</p></sec></abstract><kwd-group><kwd>Pacemaker, Artificial</kwd><kwd>Atrial Fibrillation</kwd><kwd>Atrioventricular Block</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>In electric cardiac stimulation, the dual chamber pacemaker is widely used,
especially in DDD mode, indicated in cases of atrioventricular heart block, among
others. This type of stimulation offers many clinical advantages as it can maintain
synchronization between atriums and ventricles leading to hemodynamic gain during
the cardiac cycle and improves cardiac output. This type of pacing is made by the
implantation of two leads, one in the right atrium and the other in the right
ventricle, coupled to a dual-chamber generator, each lead may sense or stimulate the
heart, thus working on demand mode according to the cardiac requirements.</p><p>The VDD mode is an alternative kind of stimulation of dual chamber pacemakers
generators. This type of cardiac stimulation can be used when the sinus node is
normally functioning<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. In this
case, only one lead is implanted, where its end remains in the right ventricle's
internal wall for stimulate and sense at this location. This same lead has a
proximal pole that is positioned within the right atrium and at this point is only
able to sense the heartbeats.</p><p>The ideal leads' position in both types of pacemakers is achieved by positioning them
with fluoroscopy aid in addition to reading the appropriate electronic measures at
the chosen location.</p><p>According to Eberhardt et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>,
the use the VDD pacemaker allows to implant in a shorter time, with less use of
fluoroscopy and fewer complications compared to DDD. Moreover, the VDD pacemaker has
less cost than DDD, considering material, hospital and medical fees<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Gon&#x000e7;alves et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> evaluated VDD implantation and
concluded that this mode of stimulation permits clinical and hemodynamic
improvement, indicating this pacemaker in all patients with atrial stability and
competence.</p><p>The implant of VDD pacemaker is not widely made in medical practice, despite the
advantages mentioned above. One hypothesis for this is the sinus node dysfunction
fear and decrease of the sensitivity by the pacemaker after its implantation, during
follow-up of these patients<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Pakarinen and Toivonen<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> state that
careful evaluation of the clinical history, electrocardiogram and adequate
radiographs are sufficient to select elderly candidates for VDD pacemaker
implantation and thus, sinus dysfunction rarely occurs under these conditions.</p><p>Although some references show that this type of pacemaker has not been used
frequently<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>, we routinely
implant VDD pacemakers in daily clinical practice without finding significant
complications inherent in this procedure; however, we observed that some patients
developed atrial fibrillation (AF) after implantation, which we also observed in DDD
implants.</p><p>Therefore, it is appropriate to question if the presence of a lead in the right
atrial wall of DDD pacemakers would increase the risk of AF induction, or, on the
other hand, the atrial pacing lead would promote more protection against this
arrhythmia, as some reports suggested<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>The objective of this study was to compare patients with DDD and VDD pacemakers with
respect to the evolution towards chronic AF and the time free of this arrhythmia in
postoperative period by evaluation in Pacemaker Clinic of Faculdade de Medicina de
Botucatu - Unesp.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This study included patients undergoing cardiac pacemaker implantation between
January 1, 1999 and December 12, 2014, attended at the Outpatient Hospital of
Faculdade de Medicina de Botucatu. Outpatient follow-up was considered the period
between January 1, 1999 and December 31, 2015.</p><sec><title>Approval by CEP</title><p>This study was approved by the Ethics and Research Committee, with CAAE:
50099715.2.0000.5411 with sound number: 1314,841.</p></sec><sec><title>Patients</title><p>From 625 we included 158 patients with dual-chamber pacemaker with 48 DDD and 110
VDD. It was accomplished a gender distribution, diagnosis, functional class of
heart failure.</p></sec><sec><title>Diagnostics for Implants Indication</title><p>The diagnostics that led indications of pacemakers implants are listed in <xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Distribution in each group: number of patients studied; sex; previous
diagnosis to the implant; functional class of heart failure; mean
follow-up of patients in months (MFM).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">DDD (number of patients)</th><th align="center" rowspan="1" colspan="1">VDD (number of patients)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Men</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">0.9703</td></tr><tr><td align="left" colspan="2" rowspan="1">Women</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">0.9703</td></tr><tr><td align="center" rowspan="7" colspan="1">Prior diagnosis</td><td align="center" rowspan="1" colspan="1">1<sup>st</sup> AVB</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">2<sup>nd</sup> AVB I</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0.8613</td></tr><tr><td align="center" rowspan="1" colspan="1">2<sup>nd</sup> AVB II</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">0.03182</td></tr><tr><td align="center" rowspan="1" colspan="1">CSH</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">_</td></tr><tr><td align="center" rowspan="1" colspan="1">RB1AVL</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">_</td></tr><tr><td align="center" rowspan="1" colspan="1">LBBB</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">_</td></tr><tr><td align="center" rowspan="1" colspan="1">BTS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">_</td></tr><tr><td align="center" rowspan="4" colspan="1">Functional class</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">0.6373</td></tr><tr><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">0.8368</td></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">0.8524</td></tr><tr><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">_</td></tr><tr><td align="center" colspan="2" rowspan="1">MFM (months) standard deviation</td><td align="center" rowspan="1" colspan="1">64.16 (or 5.35 years) 45.98</td><td align="center" rowspan="1" colspan="1">56.88 (or 4.74 years) 45.81</td><td align="center" rowspan="1" colspan="1">0.3895</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>1<sup>st</sup> AVB= first-degree atrioventricular block;
2<sup>nd</sup> AVB I=second degree atrioventricular block &#x02013;
Mobitz 1; 2<sup>nd</sup> AVB II=atrioventricular block second degree
&#x02013; Mobitz 2; CSH=carotid sinus hypersensitivity; RB1AVL=right bundle
branch block + first-degree atrioventricular block + left
anterior-superior division of the left bundle branch block;
LBBB=left bundle branch block; BTS=brady-tachy syndrome. Functional
class=The New York Heart Association functional classification (I,
II, III and IV heart failure). <italic>P</italic> value when
comparing the parameters of DDD and VDD. It was considered a
significance level of <italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Mean Time of Patient Monitoring</title><p>Average times of follow-ups of patients undergoing pacemaker implants are
indicated in <xref ref-type="table" rid="t1">Table 1</xref>. The total time in
years follow-up added all patients of each type of pacemaker was 256.66 years to
DDD and 521.41 pacemaker years to VDD. Outpatient follow-up was considered the
period between January 1, 1999 and December 31, 2015, the shortest follow-up
time of 2 months and the longest of 13 years and 11 months.</p></sec><sec><title>Exclusion Criteria</title><p>We excluded patients with third degree atrioventricular block and sinus node
disease in both groups. We also excluded cases where doubts diagnostic occurs,
information were insufficient and data were not fully reliable.</p></sec><sec><title>Groups</title><p>Patients were classified into 2 groups: Group 1, patients with DDD pacemakers;
Group 2, patients with VDD pacemakers.</p></sec><sec><title>Atrial Fibrillation</title><p>In both groups, patients who developed post-implantation AF were separated and
the time for development of AF after surgery was measured in each of them. Only
patients who entered in AF at least 2 months after surgery were included.</p></sec><sec><title>Comparison between Number and Percentage of Each Group for Evolution to
AF</title><p>Comparisons between DDD and VDD groups were made regarding the number of patients
and percentage that evolved AF within each group.</p></sec><sec><title>Actuarial Study</title><p>Free time of AF was evaluated by the curves and actuarial study in both
groups.</p></sec><sec><title>Statistical Study</title><p>One proportion test was performed to verify if there was statistical difference
between the proportions of variables such as gender, previous diagnosis and
functional class in both groups.</p><p>For the time variable, a normality test was performed and the data showed an
asymmetrical distribution. Thus, adjusted a generalized linear model with gamma
distribution to check whether there was difference between the groups with
respect to time (months) of follow-up</p><p>For the actuarial study we used the Statistical Calculations for Windows V. 1.8,
developed by Dr. Domingo Braile and Dr. Moacir Fernandes de Godoy and
implemented in Power Builder 6.6 Sc. Djalma Domingos Silva. The construction of
actuarial curves was made in Microsoft Excel program.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Number and Percentage of Patients who Developed AF</title><p>
<xref ref-type="table" rid="t2">Table 2</xref> shows the number of patients and
the percentage that has evolved to AF in both groups during the period
considered in the study.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Distribution in number (N) and percentage (%) of each type of pacemaker
which remained in sinus rhythm and which progress to atrial fibrillation
(AF) in groups DDD and VDD.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">DDD</th><th align="center" colspan="2" rowspan="1">VDD</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr><tr><th align="left" rowspan="2" colspan="1">Number of patients</th><th align="center" colspan="2" rowspan="1">48</th><th align="center" colspan="2" rowspan="1">110</th><th align="center" rowspan="2" colspan="1">&#x000a0;</th></tr><tr><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">In sinus rhythm</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">89.58</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">93.64</td><td align="center" rowspan="1" colspan="1">0.5769</td></tr><tr><td align="left" rowspan="1" colspan="1">Evolution to AF</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10.42</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">6.36</td><td align="center" rowspan="1" colspan="1">0.5769</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>It was considered a significance level of
<italic>P</italic>&#x0003c;0.05.</p><p>AF=atrial fibrillation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Actuarial Calculations and Curves</title><p>The actuarial study comparing the incidence of AF in patients with dual chamber
pacemaker DDD and VDD is shown in <xref ref-type="fig" rid="f1">Figures
1</xref>, <xref ref-type="fig" rid="f2">2</xref> and <xref ref-type="fig" rid="f3">3</xref> and <xref ref-type="table" rid="t3">Tables 3</xref> and
<xref ref-type="table" rid="t4">4</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Actuarial curve of patients with dual chamber pacemaker DDD, showing
the proportion of patients free from AF (ordinate) - expressed
values close to the corresponding points on the curve for the years
elapsed (abscissa). They also observed the curves of LLCI 95% (lower
limit confidence interval 95%) and ULCI 95% (upper limit of
confidence interval 95%).</p></caption><graphic xlink:href="rbccv-32-05-0347-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Actuarial curve of patients with dual chamber pacemaker VDD, showing
the proportion of patients free from AF (ordinate) - expressed
values close to the corresponding points on the curve for the years
elapsed (abscissa). They also observed the curves of LLCI 95% (lower
limit confidence interval 95%) and ULCI 95% (upper limit of
confidence interval 95%).</p></caption><graphic xlink:href="rbccv-32-05-0347-g02"/></fig>
</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Actuarial curve of patients with dual chamber pacemaker VDD and DDD,
showing the proportion of patients free from atrial fibrillation-AF
(ordinate) - expressed values close to the corresponding points on
the curve for the years elapsed (abscissa).</p></caption><graphic xlink:href="rbccv-32-05-0347-g03"/></fig>
</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Actuarial calculations of DDD group.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Years</th><th align="center" rowspan="1" colspan="1">PFE%</th><th align="center" rowspan="1" colspan="1">SE%</th><th align="center" rowspan="1" colspan="1">LLCI 95%</th><th align="center" rowspan="1" colspan="1">ULCI 95%</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">97.67</td><td align="center" rowspan="1" colspan="1">2.30</td><td align="center" rowspan="1" colspan="1">93.10</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">94.99</td><td align="center" rowspan="1" colspan="1">3.46</td><td align="center" rowspan="1" colspan="1">88.21</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">91.82</td><td align="center" rowspan="1" colspan="1">4.57</td><td align="center" rowspan="1" colspan="1">82.27</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">91.82</td><td align="center" rowspan="1" colspan="1">4.57</td><td align="center" rowspan="1" colspan="1">82.27</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">87.55</td><td align="center" rowspan="1" colspan="1">6.03</td><td align="center" rowspan="1" colspan="1">75.73</td><td align="center" rowspan="1" colspan="1">99.37</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">87.55</td><td align="center" rowspan="1" colspan="1">6.03</td><td align="center" rowspan="1" colspan="1">75.73</td><td align="center" rowspan="1" colspan="1">99.37</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr><tr><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">81.90</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">66.51</td><td align="center" rowspan="1" colspan="1">97.29</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>PFE%= proportion of patients free of events (atrial fibrillation);
SE%= standard error; LLCI 95%= lower limit of confidence interval
95%; ULCI 95%= upper limit of confidence interval 95%</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Actuarial calculations of VDD group.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Years</th><th align="center" rowspan="1" colspan="1">PFE%</th><th align="center" rowspan="1" colspan="1">SE%</th><th align="center" rowspan="1" colspan="1">LLCI 95%</th><th align="center" rowspan="1" colspan="1">ULCI 95%</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">97.40</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">93.85</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">97.40</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">93.85</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">97.40</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">93.85</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">95.08</td><td align="center" rowspan="1" colspan="1">2.89</td><td align="center" rowspan="1" colspan="1">89.41</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">92.20</td><td align="center" rowspan="1" colspan="1">3.99</td><td align="center" rowspan="1" colspan="1">84.38</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">88.85</td><td align="center" rowspan="1" colspan="1">5.06</td><td align="center" rowspan="1" colspan="1">78.93</td><td align="center" rowspan="1" colspan="1">98.77</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">84.72</td><td align="center" rowspan="1" colspan="1">6.29</td><td align="center" rowspan="1" colspan="1">72.39</td><td align="center" rowspan="1" colspan="1">97.05</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">84.72</td><td align="center" rowspan="1" colspan="1">6.29</td><td align="center" rowspan="1" colspan="1">72.39</td><td align="center" rowspan="1" colspan="1">97.05</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">79.25</td><td align="center" rowspan="1" colspan="1">7.91</td><td align="center" rowspan="1" colspan="1">63.74</td><td align="center" rowspan="1" colspan="1">94.76</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">79.25</td><td align="center" rowspan="1" colspan="1">7.91</td><td align="center" rowspan="1" colspan="1">63.74</td><td align="center" rowspan="1" colspan="1">94.76</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">79.25</td><td align="center" rowspan="1" colspan="1">7.91</td><td align="center" rowspan="1" colspan="1">63.74</td><td align="center" rowspan="1" colspan="1">94.76</td></tr><tr><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">79.25</td><td align="center" rowspan="1" colspan="1">7.91</td><td align="center" rowspan="1" colspan="1">63.74</td><td align="center" rowspan="1" colspan="1">94.76</td></tr><tr><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">79.25</td><td align="center" rowspan="1" colspan="1">7.91</td><td align="center" rowspan="1" colspan="1">63.74</td><td align="center" rowspan="1" colspan="1">94.76</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>PFE%= proportion of patients free of events (atrial fibrillation);
SE%= standard error; LLCI 95%= lower limit of confidence interval
95%; ULCI 95%= upper limit of confidence interval 95%</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The concept VDD pacemaker was designed in 1973, but only became commercially
available in the 80s<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Mond et
al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>, in a study
performed in 2005 by Cardiac Pacing and ICD Survey, which compared the use of
pacemakers in 43 countries, Brazil ranked fourth in a VDD use in percentage values,
surpassed by Spain (20%), Japan (18%) and Italy (11%). According to this study, in
Brazil 53% of pacemakers used was DDD (R), 34% VVI (R), 9% VDD, 4% biventricular and
less than 1% AAI (R). During the period considered in this work we routinely use the
VDD pacemaker. It can be seen that the VDD group is bigger (110 patients) than DDD
group (48 patients).</p><p>Eberhardt et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> conducted a
retrospective study in 1884 patients who received unicameral (VVI, 610 patients) and
bicameral pacemakers (VDD, 371 patients, and DDD, 903 patients). Surgeon's
experience was considered in three levels according to the number of previous
implants made before the study (low: less than 50 implants; middle: between 50 and
100 implants, and high: over 100 implants). They observed that the DDD pacemaker
requires longer use of fluoroscopy when implanted by surgeons with low or middle
levels of experience, while this time is substantially reduced with higher level of
experience. The risk of complications in procedures performed by surgeons with low
and middle levels of experience were significantly higher for implants of DDD
pacemakers, compared to VDD or VVI. However, this difference disappears when
operations were performed by surgeons with better expertise.</p><p>Wiegand et al.<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> conducted a study
in order to compare costs between the implants of DDD and VDD pacemakers. The
authors state that using VDD pacemaker, the overall cost of an uncomplicated implant
(including prostheses) can be reduced by 9% (EUR 518 per patient in this study).
They concluded therefore that the treatment with VDD pacemaker promotes a
significant cost reduction compared to DDD, without loss of efficacy. Therefore, the
single lead used in VDD pacemaker can promote a satisfactory cost-benefit ratio in
the treatment of patients with high-grade atrioventricular block with normal sinus
node function, when considering the use of dual-chamber pacemaker.</p><p>Given these reports, it is curious the fact that the VDD pacemaker is less used than
would be expected. Schaer et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> claim that, in clinical practice, VDD pacemaker has an
excellent performance in atrioventricular block patients with a presumed normal
function of the sinus node, with very low incidence of need for review by loss of
atrial sensitivity (2%) and rarely requiring reintervention for DDD pacemaker
implant due sinus node dysfunction (1%). According to the authors, the main reason
for reprogramming the VDD pacemaker to VVI is the beginning of permanent AF.</p><p>Marchandise et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, in a
prospective, non-randomized study, compared patients with symptomatic
atrioventricular block who received VDD and DDD pacemakers. According to the
authors, despite the several advantages offered by the pacemaker VDD, the main
disadvantage is that patients develop a greater loss of atrial detection compared to
DDD. However, it was not found other differences between the two types of pacemaker
that could lead to clinical impact on the incidence of AF, myocardial infarction,
dilated cardiomyopathy or mortality.</p><p>We have not included in our study patients with a previous diagnosis of sinus node
disease and third degree atrioventricular blocking, intending to become more
homogeneous groups, considering 107 cases of sick sinus syndrome in DDD and 0 in VDD
group. In addition, the number of patients with third degree atrioventricular block
was 84 in DDD and 276 in VDD group. Considering this relevant numerical difference
of third degree atrioventricular blocking, we also opted for the exclusion of
patients with this type of blocking. This decision resulted in a decrease in the
number of patients studied, but we believe that the comparison between the groups
was best suited.</p><p>Comparing VDD and DDD groups we found no differences with statistical significance
between sex and functional class or follow-up average time. Regarding the pacemaker
indication, we observed that most of cases was second degree atrioventricular block
Mobitz I and II, being that in the VDD group the second degree atrioventricular
block Mobitz II was significantly more present (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>Although the percentage of patients who developed AF during the period studied was
lower in VDD group (6.36%) than in DDD group (10.42%), there was no statistical
significant difference between them (<xref ref-type="table" rid="t2">Table
2</xref>), corroborating the results of Marchandise et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, which also found no differences in
this sense, even though they have found greater loss of atrial detection in VDD
pacemaker.</p><p>Wiegand et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> found that the
occurrence of sinus node disease is rare in patients with isolated atrioventricular
block and the incidence of atrial tachyarrhythmia in patients undergoing pacemaker
implantation DDD and VDD were similar.</p><p>With the actuarial study we observed that the two actuarial curves were close all the
time. In the early years, the curve of VDD group is positioned slightly above DDD,
but this position is reversed in the last years of follow-up. Thus, we believe that
the closeness of both curves and the actuarial calculations do not demonstrate a
relevant difference in length of time which patients with VDD and DDD pacemakers
were free of AF (<xref ref-type="fig" rid="f1">Figures 1</xref>, <xref ref-type="fig" rid="f2">2</xref> and <xref ref-type="fig" rid="f3">3</xref>,
<xref ref-type="table" rid="t3">Tables 3</xref> and <xref ref-type="table" rid="t4">4</xref>).</p><p>According to Pakarinen and Toivonen<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, the VDD pacemaker should not be used in patients with
paroxysmal AF and increased size of heart due to higher probability of loss of
atrial function with progressive evolution to AF.</p><p>The results obtained combined with reports in the literature (lower incidence of
complications, shorter time of use of fluoroscopy for the implant, lower cost,
simpler system with easier implantation) leads us to believe that VDD pacemaker
remains a good option when duly indicated. In selecting patients which would receive
this type of pacemaker (VDD) is needed careful evaluation of clinical history with
electrocardiographic and radiological appropriate study, thus, in this case, the
loss of atrial detection and/or AF rarely will develop.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The absence of a lead in the right atrium, in the case of VDD pacemakers, besides
promoting fewer complications, simplifying the surgery and having a lower cost,
seems not interfere in the development of AF when compared to DDD pacemaker, without
loss of its efficiency.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NLKLC</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and design study; realization
of operations and/or trials; analysis and/or data interpretation;
manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RRA</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MLF</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASM</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AMG</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LRG</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TBT</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Faculdade de Medicina de Botucatu (Unesp),
Botucatu, SP, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>Eloisa Paschoalinotto for collaboration in the statistical analysis.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>DiMarco</surname><given-names>JP</given-names></name><name><surname>Ellenbogen</surname><given-names>KA</given-names></name><name><surname>NA 3rd</surname><given-names>Estes</given-names></name><name><surname>Freedman</surname><given-names>RA</given-names></name><name><surname>Gettes</surname><given-names>LS</given-names></name><etal/></person-group><article-title>ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac
rhythm abnormalities: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2008</year><volume>117</volume><issue>21</issue><fpage>e350</fpage><lpage>e408</lpage><pub-id pub-id-type="pmid">18483207</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhardt</surname><given-names>F</given-names></name><name><surname>Bode</surname><given-names>F</given-names></name><name><surname>Bonnemeier</surname><given-names>H</given-names></name><name><surname>Boguschewski</surname><given-names>F</given-names></name><name><surname>Schlei</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>W</given-names></name><etal/></person-group><article-title>Long term complications in single and dual chamber pacing are
influenced by surgical experience and patient morbidity</article-title><source>Heart</source><year>2005</year><volume>91</volume><issue>4</issue><fpage>500</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">15772212</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiegand</surname><given-names>UK</given-names></name><name><surname>Potratz</surname><given-names>J</given-names></name><name><surname>Bode</surname><given-names>F</given-names></name><name><surname>Schreiber</surname><given-names>R</given-names></name><name><surname>Bonnemeier</surname><given-names>H</given-names></name><name><surname>Peters</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cost-effectiveness of dual-chamber pacemaker therapy: does single
lead VDD pacing reduce treatment costs of atrioventricular
block?</article-title><source>Eur Heart</source><year>2001</year><volume>22</volume><issue>2</issue><fpage>174</fpage><lpage>180</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>LAA</given-names></name><name><surname>Reis</surname><given-names>FAR</given-names><suffix>Filho</suffix></name><name><surname>Lima</surname><given-names>LCM</given-names></name><name><surname>Gomes</surname><given-names>MC</given-names></name><name><surname>Mota</surname><given-names>RG</given-names></name><name><surname>Miranda</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Initial experience of a single lead VDD pacing
system</article-title><source>Rev Bras Cir Cardiovasc</source><year>1998</year><volume>13</volume><issue>3</issue><fpage>263</fpage><lpage>268</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchandise</surname><given-names>S</given-names></name><name><surname>Scav&#x000e9;e</surname><given-names>C</given-names></name><name><surname>le Polain de Waroux</surname><given-names>JB</given-names></name><name><surname>Meester</surname><given-names>C</given-names></name><name><surname>Vanoverschelde</surname><given-names>JL</given-names></name><name><surname>Debbas</surname><given-names>N</given-names></name></person-group><article-title>Long-term follow-up of DDD and VDD pacing: a prospective
non-randomized single-center comparison of patients with symptomatic
atrioventricular block</article-title><source>Europace</source><year>2012</year><volume>14</volume><issue>4</issue><fpage>496</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">22071380</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakarinen</surname><given-names>S</given-names></name><name><surname>Toivonen</surname><given-names>L</given-names></name></person-group><article-title>Pre-implant determinants of adequate long-term function of single
lead VDD pacemakers</article-title><source>Europace</source><year>2002</year><volume>4</volume><issue>2</issue><fpage>137</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">12135244</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mond</surname><given-names>HG</given-names></name><name><surname>Irwin</surname><given-names>M</given-names></name><name><surname>Ector</surname><given-names>H</given-names></name><name><surname>Proclamer</surname><given-names>A</given-names></name></person-group><article-title>The world survey of cardiac pacing and
cardioverter-defibrillators: calendar year 2005 an International Cardiac
Pacing and Electrophysiology Society (ICPES) project</article-title><source>Pacing Clin Electrophysiol</source><year>2008</year><volume>31</volume><issue>9</issue><fpage>1202</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">18834475</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenbogen</surname><given-names>KA</given-names></name></person-group><article-title>Pacing therapy for prevention of atrial
fibrillation</article-title><source>Heart Rhythm</source><year>2007</year><volume>4</volume><issue>3 Suppl</issue><fpage>S84</fpage><lpage>S87</lpage><pub-id pub-id-type="pmid">17336892</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurpan</surname><given-names>I</given-names></name><name><surname>Lipar</surname><given-names>L</given-names></name><name><surname>Zizek</surname><given-names>D</given-names></name><name><surname>Boute</surname><given-names>W</given-names></name><name><surname>Vidmar</surname><given-names>M</given-names></name><name><surname>GabrijeLcic</surname><given-names>T</given-names></name><etal/></person-group><article-title>Retrospective analysis of mode survival, reliability of atrial
sensing and incidence of atrial tachyarrhythmias in 307 single-lead VDD
pacemaker patients</article-title><source>Europace</source><year>2006</year><volume>8</volume><issue>10</issue><fpage>855</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">16891329</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaer</surname><given-names>BA</given-names></name><name><surname>Weinbacher</surname><given-names>M</given-names></name><name><surname>Zellweger</surname><given-names>MJ</given-names></name><name><surname>Sticherling</surname><given-names>C</given-names></name><name><surname>Oswald</surname><given-names>S</given-names></name></person-group><article-title>Value of VDD-pacing systems in patients with atrioventricular
block: experience over a decade</article-title><source>Int J Cardiol</source><year>2007</year><volume>122</volume><issue>3</issue><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">17289175</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiegand</surname><given-names>UK</given-names></name><name><surname>Bode</surname><given-names>F</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Brandes</surname><given-names>A</given-names></name><name><surname>Haase</surname><given-names>H</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Development of sinus node disease in patients with AV block:
implications for single lead VDD pacing</article-title><source>Heart</source><year>1999</year><volume>81</volume><issue>6</issue><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">10336914</pub-id></element-citation></ref></ref-list></back></article>